Characteristics of patients with COVID-19
| . | Severe COVID-19 (n = 29) . |
|---|---|
| Demographic characteristics | |
| Age, median (range) | 63 (19-85) |
| Male sex, n (%) | 24 (82.7) |
| BMI, median (range) | 28.4 (19.7-55.6) |
| SAPS II, median (range) | 49.0 (18.0-84.0) |
| Baseline SOFA, median (range) | 5 (3-13) |
| Coexisting conditions, n (%) | |
| Hypertension | 17 (58.6) |
| Diabetes mellitus | 10 (34.5) |
| Dyslipidemia | 5 (17.2) |
| Previous myocardial infarction | 3 (10.3) |
| Chronic respiratory disease | 2 (7.1) |
| Obesity | 11 (37.9) |
| Chronic cardiac disease | 5 (17.2) |
| Chronic liver disease | 1 (3.4) |
| Chronic kidney disease | 3 (10.3) |
| Thromboembolic disease | 4 (13.8) |
| Prior antiplatelet agent | 4 (13.8) |
| Anticoagulation | 2 (7.4) |
| Hydroxychloroquine | 3 (10.3) |
| Dexamethasone | 21 (72.4) |
| β-lactams antibiotics | 25 (86.2) |
| Neuromuscular-blocking drugs | 20 (68.9) |
| Enoxaparin | 21 (72.4) |
| Biology (at inclusion), median (range) | |
| CRP (mg/mL) | 107.0 (6.4-237.7) |
| Leukocytes (g/L) | 8.3 (4.5-29.8) |
| Lymphocytes (g/L) | 0.8 (0.2-8.3) |
| Neutrophiles (g/L) | 7.2 (3.2-23.8) |
| Platelet count (g/L) | 194 (65-521) |
| MPV (fL) | 10.3 (9.1-13.4) |
| D-dimers (ng/mL) | 910 (500-4000) |
| Fibrinogen (g/L) | 7.0 (4.2-7.9) |
| Outcomes, median (range) or n (%) | |
| Ratio PaO2/FiO2 | 148.5 (67.0-320.0) |
| High flow oxygen, n (%) | 7 (24.2) |
| Invasive mechanical ventilation, n (%) | 22 (75.8) |
| Duration of mechanical ventilation (d) | 18.5 (3.0-83.0) |
| ICU LOS (d) | 17.0 (1.0-85.0) |
| Hospital LOS (d), median (range) | 26.0 (3.0-155.0) |
| Death, n (%) | 10 (34.5) |
| . | Severe COVID-19 (n = 29) . |
|---|---|
| Demographic characteristics | |
| Age, median (range) | 63 (19-85) |
| Male sex, n (%) | 24 (82.7) |
| BMI, median (range) | 28.4 (19.7-55.6) |
| SAPS II, median (range) | 49.0 (18.0-84.0) |
| Baseline SOFA, median (range) | 5 (3-13) |
| Coexisting conditions, n (%) | |
| Hypertension | 17 (58.6) |
| Diabetes mellitus | 10 (34.5) |
| Dyslipidemia | 5 (17.2) |
| Previous myocardial infarction | 3 (10.3) |
| Chronic respiratory disease | 2 (7.1) |
| Obesity | 11 (37.9) |
| Chronic cardiac disease | 5 (17.2) |
| Chronic liver disease | 1 (3.4) |
| Chronic kidney disease | 3 (10.3) |
| Thromboembolic disease | 4 (13.8) |
| Prior antiplatelet agent | 4 (13.8) |
| Anticoagulation | 2 (7.4) |
| Hydroxychloroquine | 3 (10.3) |
| Dexamethasone | 21 (72.4) |
| β-lactams antibiotics | 25 (86.2) |
| Neuromuscular-blocking drugs | 20 (68.9) |
| Enoxaparin | 21 (72.4) |
| Biology (at inclusion), median (range) | |
| CRP (mg/mL) | 107.0 (6.4-237.7) |
| Leukocytes (g/L) | 8.3 (4.5-29.8) |
| Lymphocytes (g/L) | 0.8 (0.2-8.3) |
| Neutrophiles (g/L) | 7.2 (3.2-23.8) |
| Platelet count (g/L) | 194 (65-521) |
| MPV (fL) | 10.3 (9.1-13.4) |
| D-dimers (ng/mL) | 910 (500-4000) |
| Fibrinogen (g/L) | 7.0 (4.2-7.9) |
| Outcomes, median (range) or n (%) | |
| Ratio PaO2/FiO2 | 148.5 (67.0-320.0) |
| High flow oxygen, n (%) | 7 (24.2) |
| Invasive mechanical ventilation, n (%) | 22 (75.8) |
| Duration of mechanical ventilation (d) | 18.5 (3.0-83.0) |
| ICU LOS (d) | 17.0 (1.0-85.0) |
| Hospital LOS (d), median (range) | 26.0 (3.0-155.0) |
| Death, n (%) | 10 (34.5) |
None of the patients were under extracorporeal membrane oxygenation. The median for blood sampling was 4 days after ICU admission. No patient with the ο variant was included in the study.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; LOS, length of stay; MPV, mean platelet volume; SAPS II, simplified acute physiology score; SOFA, sepsis-related organ failure assessment.